Opsynvi
Opsynvi is a prescription medication combining macitentan and tadalafil, designed as a single-tablet combination therapy for adults with pulmonary arterial hypertension (PAH). It works by targeting two different pathways involved in blood vessel constriction, helping to improve exercise capacity and slow disease progression. This combination simplifies treatment by delivering two proven PAH therapies in one convenient daily tablet.
Opsynvi is a combination PAH medication that helps relax blood vessels in the lungs to improve blood flow and exercise ability.
Key facts at a glance
- RxNorm
- 2677766
- Generic
- Opsynvi
- Class
- brand-name
- Brands
- —
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- —
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Opsynvi is indicated for the treatment of pulmonary arterial hypertension (PAH) in adults, including those with certain types of PAH associated with connective tissue disease, to improve exercise capacity and delay clinical worsening.
Opsynvi combines two active ingredients: macitentan (an endothelin receptor antagonist) and tadalafil (a phosphodiesterase type 5 inhibitor). These agents work through complementary mechanisms to reduce pulmonary vascular resistance by blocking endothelin and enhancing nitric oxide pathways, resulting in vasodilation of the pulmonary arteries.
Opsynvi is contraindicated in pregnancy and should not be used in patients with hypersensitivity to any components. Regular monitoring of liver function and blood counts is recommended. Common side effects may include headache, anemia, and peripheral edema. Patients should avoid concurrent use with certain medications including nitrates and strong CYP3A4 inhibitors.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy